Drugs / Immune Globulin Infusion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05084053 | Jan 2022 → Oct 2025 | chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy | Takeda | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immune Globulin Infusion | “TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20).” NCT05084053 ↗ |
| Known as | IGI | “TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20).” NCT05084053 ↗ |
| Modality | Protein / enzyme biologic | “TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20).” NCT05084053 ↗ |
| Route | Subcutaneous | “Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the...” NCT05084053 ↗ |